ANAB
Price
$22.04
Change
-$0.10 (-0.45%)
Updated
Sep 25 closing price
Capitalization
616.52M
46 days until earnings call
NERV
Price
$2.17
Change
-$0.03 (-1.37%)
Updated
Sep 25 closing price
Capitalization
15.14M
45 days until earnings call
Interact to see
Advertisement

ANAB vs NERV

Header iconANAB vs NERV Comparison
Open Charts ANAB vs NERVBanner chart's image
AnaptysBio
Price$22.04
Change-$0.10 (-0.45%)
Volume$391.41K
Capitalization616.52M
Minerva Neurosciences
Price$2.17
Change-$0.03 (-1.37%)
Volume$17.01K
Capitalization15.14M
ANAB vs NERV Comparison Chart in %
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. NERV commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Buy and NERV is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (ANAB: $22.04 vs. NERV: $2.16)
Brand notoriety: ANAB and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 76% vs. NERV: 61%
Market capitalization -- ANAB: $616.52M vs. NERV: $15.14M
ANAB [@Biotechnology] is valued at $616.52M. NERV’s [@Biotechnology] market capitalization is $15.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 1 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 1 green, 4 red.
According to our system of comparison, NERV is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 4 TA indicator(s) are bullish while NERV’s TA Score has 6 bullish TA indicator(s).

  • ANAB’s TA Score: 4 bullish, 4 bearish.
  • NERV’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NERV is a better buy in the short-term than ANAB.

Price Growth

ANAB (@Biotechnology) experienced а +4.55% price change this week, while NERV (@Biotechnology) price change was +5.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 11, 2025.

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($617M) has a higher market cap than NERV($15.1M). ANAB YTD gains are higher at: 66.465 vs. NERV (-2.548). NERV has higher annual earnings (EBITDA): 11.2M vs. ANAB (-59.63M). ANAB has more cash in the bank: 266M vs. NERV (15.2M). NERV has less debt than ANAB: NERV (0) vs ANAB (15.1M). ANAB has higher revenues than NERV: ANAB (123M) vs NERV (0).
ANABNERVANAB / NERV
Capitalization617M15.1M4,086%
EBITDA-59.63M11.2M-532%
Gain YTD66.465-2.548-2,609%
P/E RatioN/A1.46-
Revenue123M0-
Total Cash266M15.2M1,750%
Total Debt15.1M0-
FUNDAMENTALS RATINGS
ANAB vs NERV: Fundamental Ratings
ANAB
NERV
OUTLOOK RATING
1..100
1363
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5654
P/E GROWTH RATING
1..100
70100
SEASONALITY SCORE
1..100
n/a49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for ANAB (84). This means that NERV’s stock grew somewhat faster than ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as NERV (100). This means that ANAB’s stock grew similarly to NERV’s over the last 12 months.

ANAB's SMR Rating (100) in the Biotechnology industry is in the same range as NERV (100). This means that ANAB’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (54) in the Biotechnology industry is in the same range as ANAB (56). This means that NERV’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's P/E Growth Rating (70) in the Biotechnology industry is in the same range as NERV (100). This means that ANAB’s stock grew similarly to NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABNERV
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NMIAX30.01N/A
N/A
Columbia Large Cap Enhanced Core A
FSAVX65.48N/A
N/A
Fidelity Select Automotive Port
CBAIX49.18N/A
N/A
Calvert Balanced I
JDICX16.90N/A
N/A
JHancock Disciplined Value Intl C
BHCUX18.12-0.30
-1.61%
Baron Health Care R6

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DNLI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-1.14%
DNLI - NERV
34%
Loosely correlated
-0.37%
ANAB - NERV
33%
Poorly correlated
-0.45%
IDYA - NERV
32%
Poorly correlated
+0.08%
MLTX - NERV
31%
Poorly correlated
+4.51%
GBIO - NERV
31%
Poorly correlated
-0.69%
More